FDA Approves Once-Daily Jakafi XR for Blood Disorders
WILMINGTON, DE — Incyte (Nasdaq: INCY) recently received U.S. Food and Drug Administration approval for Jakafi XR, a once-daily extended-release version of ruxolitinib, giving patients with several chronic blood disorders …
FDA Approves Once-Daily Jakafi XR for Blood Disorders Read More